Invasive Ductal Carcinoma (IDC): Symptoms, Diagnosis, Stages & Treatment

Invasive ductal carcinoma (IDC) is the most common type of breast cancer — an invasive cancer that begins in the milk ducts and has grown through the duct wall into surrounding breast tissue, giving it the potential to spread to lymph nodes and, if untreated, distant organs. IDC is not one single disease: treatment depends heavily on tumor grade, hormone receptor (ER/PR) status, HER2 status, tumor size, lymph node involvement, and increasingly, genomic risk testing. Treatment typically combines surgery (lumpectomy or mastectomy) with some combination of chemotherapy, hormone therapy, HER2-targeted therapy, and radiation — the exact combination is genuinely individual, not standard across patients.

If you or a family member has just received an IDC diagnosis, this guide walks through what the pathology report actually means, how staging and biomarkers shape your treatment options, what current treatment looks like by stage and tumor biology, and what international patients should know about pursuing treatment in India.

What Does IDC Mean?

Invasive ductal carcinoma is cancer that began in the cells lining a milk duct and has broken through the duct’s basement membrane to invade the surrounding fatty and connective breast tissue. Once cancer cells cross this boundary, they gain the potential — not the certainty, but the potential — to travel through the lymphatic system or bloodstream to lymph nodes and other parts of the body. This invasive potential is exactly what separates IDC from non-invasive conditions like DCIS.

IDC is the most commonly diagnosed type of breast cancer, accounting for roughly 70–80% of invasive breast cancer diagnoses in most published series, though it is genuinely not one biological disease. Two patients both diagnosed with “IDC” can have completely different tumor grade, hormone receptor status, HER2 status, and genomic risk — and therefore completely different treatment plans and outlooks. The diagnosis name tells you where the cancer started and that it’s invasive; it does not, by itself, tell you how it will be treated or what your prognosis is.

IDC vs. DCIS vs. Invasive Lobular Carcinoma

These three terms are frequently confused on pathology reports and in search results. Here’s how they differ:

DCIS is non-invasive. IDC is invasive. This is not a minor technical distinction — it changes staging, the relevance of lymph node evaluation, and the entire treatment approach. Not every DCIS progresses to invasive cancer, and a DCIS diagnosis does not mean IDC is coming.

IDC and ILC are both invasive breast cancers but arise from different cell types and can have different imaging characteristics, growth patterns, and — in a meaningful subset of cases different receptor profiles (ILC is more frequently ER-positive). Neither is universally “more serious” than the other; tumor biology and stage matter more than the histologic label alone when it comes to prognosis.

Symptoms and Warning Signs

IDC may be found through screening before any symptoms develop, or it may present with a noticeable breast change. Neither pattern is more or less “real” than the other.

Possible symptoms include:

• A breast lump or thickened area
• A change in breast size or shape
• Skin dimpling
• Nipple inversion (turning inward)
• Nipple discharge
• Nipple or areolar skin changes
• Breast discomfort or tenderness
• Swelling of part or all of the breast
• Enlarged lymph nodes under the arm

Not every breast lump is cancer most breast lumps, particularly in younger women, turn out to be benign. And absence of symptoms does not mean absence of cancer — a significant proportion of IDC is found through routine screening mammography, before any change is noticeable to the patient. Both points matter: don’t panic over every lump, and don’t assume a normal self-exam means nothing needs checking if a screening mammogram flags something.

Screening vs. Symptomatic Detection

IDC can be identified in several ways:

• Screening mammography, in patients with no symptoms, following age- and risk-based screening guidelines
• After a patient notices a breast change and seeks evaluation
• During evaluation of a palpable lump found on self- or clinical exam
• During further work-up of an imaging abnormality found for another reason

Screening recommendations (starting age, frequency, and whether supplemental imaging is used) depend on individual risk factors, family history, and local/national guidelines, which vary by country. There is no single universal schedule appropriate for every reader discuss your personal screening plan with your own physician based on your risk profile.

How Invasive Ductal Carcinoma Is Diagnosed

Diagnosis requires a combination of clinical examination, imaging, and tissue biopsy. Imaging can identify a suspicious area, but only biopsy and pathology examination can confirm IDC.

The typical pathway:

• Clinical breast examination
• Mammography — often the first imaging step
• Breast ultrasound — frequently used alongside mammography, particularly in dense breast tissue
• Breast MRI — used selectively, for example to assess disease extent in certain cases
• Core needle biopsy — the key step that removes tissue for pathology examination
• Lymph node biopsy, where clinically indicated
• Pathology review, including ER, PR, and HER2 testing

Core Needle Biopsy

Core needle biopsy, often image-guided, is the standard way to obtain tissue for diagnosis. It allows the pathologist to confirm invasive carcinoma, determine histologic type and grade, and run receptor testing — all before any surgery is planned. Not every patient’s biopsy approach is identical; your radiologist or surgeon selects the technique based on how the abnormality appears on imaging.

Understanding the IDC Pathology Report

Your pathology report is the single most important document shaping your treatment plan. In plain language, it typically includes:

• Confirmation of invasive ductal carcinoma (versus another histologic type)
• Tumor grade (see below)
• Tumor size
• Lymphovascular invasion — whether cancer cells are seen within blood or lymphatic vessels, which can carry prognostic relevance
• Margins — for surgical specimens, whether cancer cells reach the edge of the removed tissue
• Lymph node involvement, if nodes were sampled
• ER, PR, and HER2 status
• Other biomarkers relevant to your specific case

This report, combined with imaging and clinical findings, is what your oncology team uses to determine prognosis and build your treatment plan — not any one line item in isolation.

Tumor Grade: Grade 1, 2, and 3

Grade describes how abnormal the cancer cells look under the microscope and how closely they resemble normal breast cells which correlates with how the tumor tends to behave.

• Grade 1 (low grade): Cells look closer to normal, tend to grow more slowly
• Grade 2 (intermediate grade): Features between grade 1 and grade 3
• Grade 3 (high grade): Cells look markedly abnormal, tend to grow and divide more quickly

Grade is not the same as stage. It describes the biological aggressiveness of the cancer cells; stage describes how far the disease has spread anatomically. A patient can have an early-stage but high-grade tumor, or a later-stage but lower-grade tumor — both pieces of information are used together, not interchangeably, and grade alone does not predict an individual’s outcome.

ER, PR, and HER2 Status

This biomarker panel, run on every IDC diagnosis, fundamentally shapes the entire treatment plan.

ER-positive (estrogen receptor-positive): cancer cells express receptors that respond to estrogen, making endocrine (hormone) therapy relevant to treatment.

PR-positive (progesterone receptor-positive): cancer cells express progesterone receptors, generally assessed alongside ER status.

Important: hormone receptor-positive disease is not automatically “low-risk” or “slow-growing” some hormone receptor-positive tumors are high-grade and behave aggressively. Receptor status determines whether endocrine therapy is relevant, not how serious the cancer is on its own.

HER2 Status

HER2-positive means tumor cells show overexpression or amplification of the HER2 protein, determined through a combination of immunohistochemistry (IHC) and, where results are equivocal, in situ hybridization testing (ISH/FISH). HER2-positive disease is treated with HER2-targeted therapy in addition to other systemic treatment.

HER2-low and HER2-ultralow are more recently defined categories — tumors that show some HER2 expression but don’t meet the threshold for conventional “HER2-positive” classification. This distinction has become clinically meaningful, particularly in the metastatic setting: the FDA expanded approval of the HER2-directed antibody-drug conjugate trastuzumab deruxtecan to include HER2-ultralow metastatic breast cancer in January 2025, based on the DESTINY-Breast06 trial. HER2-low/ultralow is not the same as HER2-positive disease and is not treated with the same standard HER2-targeted regimens used for HER2-positive early-stage disease — this is a distinction worth explicitly asking your oncologist about if your report uses either term.

Triple-Negative IDC

Triple-negative breast cancer means the tumor is ER-negative, PR-negative, and HER2-negative. This is a distinct biological category — not simply “IDC without a special treatment,” but a specific tumor biology treated differently from hormone receptor-positive or HER2-positive disease.

Current treatment for early-stage, higher-risk triple-negative disease commonly combines chemotherapy with immunotherapy (pembrolizumab) in the neoadjuvant setting, based on trial evidence (KEYNOTE-522) showing improved outcomes with this combination. Not every triple-negative patient is automatically a candidate for immunotherapy — eligibility depends on stage, risk category, and current guideline criteria, assessed by your treating oncologist.

In the metastatic setting, triple-negative disease treatment options include chemotherapy, immunotherapy where biomarkers support it, and targeted therapies such as antibody-drug conjugates for selected patients — an evolving area best discussed directly with your oncology team for current options.

Genomic and Genetic Testing

Two distinct types of testing are relevant, and they answer different questions:

Germline genetic testing (BRCA1/BRCA2 and other hereditary cancer genes) looks at inherited mutations present in every cell of your body, relevant to both your treatment options and your family’s future risk. This may be recommended based on age at diagnosis, family history, or specific tumor characteristics.

Multigene genomic assays (tumor-based tests looking at gene expression within the cancer itself) are used specifically to help guide the chemotherapy decision in selected patients with hormone receptor-positive, HER2-negative, early-stage breast cancer, when it’s genuinely unclear whether the benefit of adding chemotherapy to hormone therapy outweighs its toxicity. These assays estimate genomic recurrence risk and, in some patients, can support the decision to safely omit chemotherapy — a clinically meaningful development in modern breast cancer care.

Not every patient needs every test. Whether genetic or genomic testing applies to your case depends on your specific pathology, age, family history, and stage — a genetic counselor or your oncologist can clarify what’s relevant to you specifically.

Invasive Ductal Carcinoma Stages

IDC staging uses the TNM system:

• T (Tumor): size and local extent of the primary tumor
• N (Nodes): whether and how extensively regional lymph nodes are involved
• M (Metastasis): whether distant spread is present

These combine into overall stages:

Anatomic Stage vs. Prognostic Stage

Modern breast cancer staging (per AJCC criteria) can incorporate tumor grade, ER, PR, and HER2 status alongside the anatomic TNM findings to generate a prognostic stage, which can differ from the anatomic stage alone. In practice, this means two patients with identical tumor size and lymph node findings can be assigned different overall stages if their biomarker profiles differ. This is a genuinely useful refinement, but it also means you shouldn’t assume your stage is determined by tumor size and lymph nodes alone — ask your oncologist to walk through how your specific biomarkers factored into your staging.

Treatment by Stage

There is no single treatment for IDC. Treatment depends on stage, ER/PR and HER2 status, grade, tumor size, lymph node status, genomic risk (where tested), menopausal status, germline mutation status where relevant, response to any neoadjuvant treatment, and overall health.

Stage I: Generally involves surgery, with radiation where indicated (typically after breast-conserving surgery), endocrine therapy for hormone receptor-positive disease, HER2-targeted therapy for HER2-positive disease, and chemotherapy for selected higher-risk patients based on grade and genomic testing where applicable. Not every Stage I patient needs chemotherapy — this is one of the areas genomic testing has most directly changed practice.

Stage II: Can involve either surgery first or neoadjuvant systemic therapy first, depending on tumor biology and size, followed by adjuvant therapy, radiation, endocrine therapy, HER2-targeted therapy, and/or chemotherapy as indicated by biomarkers and risk.

Stage III: Generally represents locally advanced disease. Many Stage III patients receive systemic therapy (chemotherapy, often with HER2-targeted therapy or immunotherapy depending on biology) before surgery, followed by surgery and radiation. Stage III is not automatically incurable — it reflects a more extensive disease burden requiring a more intensive, coordinated treatment approach.

Stage IV (metastatic): Treatment is primarily systemic, tailored to tumor biology (see Metastatic IDC below). Local treatments, including surgery, may be used selectively in specific circumstances but are not the primary treatment approach for distant metastatic disease.

Surgery: Lumpectomy vs. Mastectomy

Breast-conserving surgery (lumpectomy) removes the tumor along with a margin of surrounding healthy tissue, preserving most of the breast.

Mastectomy removes the entire breast.

Eligibility for breast conservation depends on:

• Tumor size relative to breast size
• Tumor location
• Whether the disease is present in more than one area (multifocality)
• Genetic risk (some patients with high-risk mutations choose mastectomy for risk-reduction reasons independent of what breast conservation would technically allow)
• Whether radiation is feasible for the patient
• Response to neoadjuvant therapy, if given
• Patient preference

Neither approach is universally “better.” For many patients, breast-conserving surgery combined with radiation offers equivalent long-term outcomes to mastectomy — but this depends entirely on individual clinical factors that only your surgical team can assess for your specific case.

Lymph Node Surgery

Sentinel lymph node biopsy removes and examines the first few lymph nodes most likely to contain cancer cells, used to assess node involvement with less extensive surgery than full dissection.

Axillary lymph node dissection removes a larger number of lymph nodes and is used in specific clinical circumstances — for example, when sentinel nodes show significant involvement, or in certain treatment pathways.

The choice between these depends on clinical findings and your specific treatment pathway — not every patient needs full axillary dissection, and this has become less common as sentinel node techniques have refined patient selection.

Neoadjuvant Therapy

Systemic treatment given before surgery may be used to shrink the tumor, treat microscopic disease early, potentially improve surgical options (including making breast conservation possible for some patients who would otherwise need mastectomy), assess how the tumor responds to treatment, and guide postoperative therapy decisions based on that response.

Neoadjuvant treatment is especially relevant for:

• HER2-positive disease
• Triple-negative disease
• Locally advanced (Stage III) disease
• Selected hormone receptor-positive disease with higher-risk features

Not every IDC patient needs treatment before surgery — many Stage I and some Stage II patients proceed directly to surgery, with systemic therapy given afterward if indicated by pathology and biomarkers.

Chemotherapy

Chemotherapy may be recommended for early-stage disease with higher-risk features, node-positive disease, triple-negative disease, HER2-positive disease (typically alongside HER2-targeted therapy), locally advanced disease, and metastatic disease. Modern decisions about whether chemotherapy is needed increasingly incorporate genomic risk testing for appropriate hormone receptor-positive, HER2-negative patients, rather than relying on stage and grade alone.

Hormone (Endocrine) Therapy

For hormone receptor-positive IDC, endocrine therapy is a central part of treatment, generally continued over an extended period (often 5–10 years).

Common categories include:

• Tamoxifen — used in both pre- and postmenopausal patients
• Aromatase inhibitors — used primarily in postmenopausal patients, or premenopausal patients combined with ovarian suppression
• Ovarian suppression, where appropriate for premenopausal patients

The specific choice depends on menopausal status, individual risk, prior treatment, and tolerance — this is an individualized prescribing decision made with your oncologist, not something this article can determine for you.

CDK4/6 Inhibitors

For hormone receptor-positive, HER2-negative disease, CDK4/6 inhibitors — abemaciclib and ribociclib among them — have become part of standard treatment in two distinct settings, with different evidence behind each:

• High-risk early-stage disease: abemaciclib and ribociclib, combined with endocrine therapy, have shown improvement in invasive disease-free survival (and, for abemaciclib, overall survival) in high-risk early-stage hormone receptor-positive/HER2-negative breast cancer.
• Advanced/metastatic disease: CDK4/6 inhibitors combined with endocrine therapy are standard first-line treatment for hormone receptor-positive, HER2-negative metastatic disease, though resistance commonly develops after a period of disease control (often around two years, based on published data), requiring a change in treatment approach at that point.

Not all hormone receptor-positive patients require a CDK4/6 inhibitor — eligibility in the early-stage setting depends specifically on risk features (tumor size, grade, node involvement) meeting criteria studied in the relevant trials.

HER2-Targeted Therapy

Current HER2-directed treatment includes several distinct agents used in different clinical contexts:

• Trastuzumab, often combined with pertuzumab for dual HER2 blockade, used in both early-stage (neoadjuvant/adjuvant) and metastatic HER2-positive disease
• Trastuzumab emtansine (T-DM1), an antibody-drug conjugate typically used for patients with residual disease after neoadjuvant treatment
• Trastuzumab deruxtecan, a more potent antibody-drug conjugate, established in metastatic HER2-positive disease and now also approved for HER2-low and HER2-ultralow metastatic disease specifically — a distinct indication from conventional HER2-positive treatment
• Additional HER2-directed agents used in specific, guideline-supported circumstances

Not every HER2-positive patient receives every one of these drugs — the specific regimen and sequence depends on whether disease is early-stage or metastatic, response to prior treatment, and whether disease is conventionally HER2-positive versus HER2-low/ultralow.

Immunotherapy

Immunotherapy (pembrolizumab) has a defined role in selected triple-negative breast cancer settings, both in the neoadjuvant early-stage setting (per KEYNOTE-522) and in specific metastatic contexts based on biomarker status. It is not standard treatment for hormone receptor-positive or HER2-positive IDC — its role is specifically tied to triple-negative tumor biology and, in the metastatic setting, additional biomarker testing.

Radiation Therapy

Radiation may be recommended after breast-conserving surgery (frequently), after mastectomy in patients with higher-risk features (such as larger tumors or significant lymph node involvement), and when regional lymph nodes require additional treatment.

Not everyone who has a mastectomy needs radiation — this depends on tumor size, margins, lymph node findings, and other risk factors your radiation oncologist assesses specifically for your case.

Treatment After Surgery: Pathological Response and Residual Disease

For patients who received neoadjuvant (before-surgery) treatment, the surgical pathology report reveals how the tumor actually responded:

Pathological complete response (pCR) means no invasive cancer is found in the breast or sampled lymph nodes at the time of surgery. This is an important prognostic marker associated with better long-term outcomes in several breast cancer subtypes, particularly HER2-positive and triple-negative disease.

Residual disease means some invasive cancer remains despite neoadjuvant treatment. This does not mean treatment failed or that cure is impossible — it provides information that can lead to escalated post-surgical treatment tailored to the specific residual findings (for example, switching to a different HER2-targeted agent, or adding additional systemic therapy for triple-negative disease). pCR is a way of measuring treatment response, not a synonym for “cured” — ongoing follow-up remains essential regardless of the result.

Metastatic IDC

Stage IV IDC is generally treated with systemic therapy, tailored specifically to tumor biology:

Hormone receptor-positive, HER2-negative: endocrine therapy combined with CDK4/6 inhibitors as a common first approach, with targeted therapies (including for HER2-low/ultralow disease, where applicable) and chemotherapy used as disease progresses or in specific clinical situations.

HER2-positive: HER2-directed therapies, often combined with chemotherapy, with antibody-drug conjugates used across treatment lines as guided by current evidence.

Triple-negative: chemotherapy, immunotherapy where biomarkers support it, and targeted therapies including antibody-drug conjugates for selected patients based on biomarker profile.

No single regimen applies to all metastatic IDC — treatment selection and sequencing is highly individualized and evolves as evidence changes, which is why ongoing engagement with your oncology team matters throughout metastatic treatment rather than a single fixed plan.

Metastatic Sites

Common sites of distant spread include bone, liver, lung, and brain. Symptoms and specific treatment considerations depend on which site(s) are involved — metastasis to one organ does not automatically determine prognosis on its own, since tumor biology and overall treatment response matter significantly.

Recurrent IDC

Recurrence can occur as:

• Local recurrence — within the breast or chest wall
• Regional recurrence — in nearby lymph nodes
• Distant recurrence — spread to other parts of the body

Treatment for recurrence depends on where it occurs, current ER/PR and HER2 status (sometimes re-tested, as receptor status can occasionally change between initial diagnosis and recurrence), previous treatments received, how long disease was controlled before recurring, and overall health. Recurrent disease requires reassessment, not automatic repetition of the original treatment plan — biology and circumstances may have changed.

Prognosis and Survival

Prognosis in IDC depends on stage, tumor biology (grade, ER/PR, HER2), lymph node status, genomic risk where tested, treatment response, presence of metastatic disease, and overall health — no single factor determines outcome on its own.

Be cautious of any source, including this one, presenting a single confident survival percentage without full context. Published statistics describe outcomes for groups of patients studied under specific treatment eras and conditions — they don’t predict any individual’s outcome. Your oncologist, who has your complete clinical picture, is the right person to discuss what current data actually means for your specific diagnosis.

Fertility and Survivorship

Systemic cancer treatment can affect menstrual function, ovarian function, fertility, and the timing of menopause. If fertility matters to you, discuss preservation options with your oncology team before treatment begins — options are generally more limited once treatment has started, and no approach can guarantee preservation.

Breast Reconstruction

Reconstruction may be considered after mastectomy, with timing depending on whether radiation is planned, overall cancer treatment sequencing, healing, and personal preference. Immediate reconstruction isn’t automatically appropriate for every patient — this is a separate conversation with a plastic/reconstructive surgeon alongside your breast surgical team.

Long-Term Follow-Up

Ongoing survivorship care typically includes clinical follow-up, imaging when indicated, bone health monitoring (particularly relevant with certain endocrine therapies), cardiac monitoring for patients who received HER2-targeted therapy given its recognized cardiac effects in some patients, management of lymphedema risk, support for menopausal symptoms, and attention to psychosocial health. There is no single universal follow-up schedule that applies to every patient — your team individualizes this based on your treatment and risk profile.

Invasive Ductal Carcinoma Treatment Cost in India

Published Indian cost figures for breast cancer treatment vary considerably depending on stage, treatment complexity, and hospital — a range that reflects genuine differences in disease extent and treatment needs rather than inconsistent pricing. Rather than one number, here’s what drives the total:

Early-stage IDC (surgery, possibly with radiation and/or endocrine therapy, with or without chemotherapy):

• Lumpectomy: commonly cited at roughly ₹1,00,000–₹2,00,000
• Mastectomy: commonly cited at roughly ₹1,50,000–₹4,00,000
• Radiation therapy: commonly cited at roughly ₹1,00,000–₹3,50,000, depending on technique and number of sessions
• Chemotherapy: commonly cited at roughly ₹55,000–₹2,00,000 per cycle, depending on drug regimen, typically across multiple cycles
• Endocrine therapy: ongoing oral medication cost over 5–10 years, generally modest per month compared to other treatment components
• Genomic testing (where used to guide the chemotherapy decision): an additional, separate cost to confirm with your hospital

Additional cost drivers for specific tumor biology:

• HER2-targeted therapy, for HER2-positive disease, represents a substantial and separate cost — published Indian pricing for a full year of trastuzumab has been cited at roughly ₹4,00,000–₹5,00,000, with the pertuzumab-trastuzumab combination reported at roughly ₹2,00,000+ per dose in some sources; biosimilar availability has meaningfully reduced trastuzumab-specific costs in recent years
• Immunotherapy (pembrolizumab), for eligible triple-negative disease, is a similarly significant additional cost continued over an extended treatment course
• CDK4/6 inhibitors, for eligible hormone receptor-positive disease, add an ongoing oral medication cost, generally lower per-month than infused targeted therapies but continued over an extended period

Locally advanced (Stage III) IDC generally costs more due to the addition of neoadjuvant systemic therapy before surgery, and often more extensive surgery and radiation.

Metastatic (Stage IV) IDC costs are typically higher and more open-ended, reflecting ongoing systemic therapy over an extended period rather than a single defined treatment course, and vary enormously depending on which targeted therapies or immunotherapy apply to the specific tumor biology.

As with the other Shifam oncology guides, the most important practical advice here is the same: explicitly confirm with any hospital or facilitator whether HER2-targeted therapy, immunotherapy, or CDK4/6 inhibitors are included in a quoted “package” price or billed separately

These targeted agents are consistently the largest source of unexpected cost escalation in real patient experience, precisely because general “breast cancer treatment cost” figures often reflect surgery, chemotherapy, and radiation alone.

The only reliable figure is an itemized estimate based on your actual pathology, staging, and biomarker results — Shifam Health can request this from a partner hospital’s breast oncology team once your reports are shared.

Why International Patients Consider India

India has become a significant destination for international breast cancer patients, driven by a combination of specialist availability, modern diagnostic and treatment infrastructure — including biosimilar availability that has meaningfully lowered targeted therapy costs in recent years — and treatment costs substantially lower than the US, UK, or Gulf region for comparable care.

Rather than a blanket claim, the more useful question is: what should you compare before choosing a center for IDC treatment?

• Does the hospital have a breast surgical oncologist with genuine experience across both breast-conserving surgery and mastectomy, including after neoadjuvant treatment?
• Is there reliable, accredited ER/PR/HER2 testing, and access to genomic assays where clinically relevant?
• Does the center offer on-site radiation therapy, avoiding the added complexity of coordinating with a separate facility?
• Is there a functioning multidisciplinary breast tumor board?
• Does the hospital have HER2-targeted therapy, immunotherapy, and CDK4/6 inhibitors readily available, with these costs transparently itemized in estimates?
• Is there a dedicated international patient department experienced with remote pathology review and itemized cost estimates?

Choosing an IDC Treatment Center

Rather than a superficial “Top 10” list, use this as an evaluation checklist:

• Breast surgical oncologist with demonstrated experience in both breast conservation and mastectomy
• Breast medical oncologist experienced in current biomarker-driven and genomic-testing-informed treatment decisions
• Breast radiologist and pathologist, including reliable HER2 and genomic testing access
• Radiation oncologist and on-site radiation facilities
• Multidisciplinary tumor board specific to breast cancer
• Reconstructive/plastic surgery availability or referral
• Metastatic cancer treatment capability, for patients who may need it
• International patient coordination team experienced with remote report review

Verify accreditation (JCI/NABH) and each specialist’s actual credentials directly with the hospital before committing.

International Patient Treatment Journey

1. Share your reports — imaging, biopsy/pathology, and ER/PR/HER2 results if already available.
2. Specialist and pathology review by a breast oncology team, including biomarker and, where relevant, genomic testing review.
3. Treatment recommendation and itemized cost estimate, explicitly clarifying whether HER2-targeted therapy, immunotherapy, or CDK4/6 inhibitors are included.
4. Hospital selection and medical visa documentation support.
5. Travel planning.
6. In-person consultation and further workup on arrival, if not already completed remotely.
7. Neoadjuvant treatment (if applicable) or surgery, followed by radiation and/or systemic therapy per your treatment plan.
8. Recovery and discharge planning.
9. Remote follow-up — including coordination of extended endocrine, HER2-targeted, or CDK4/6 inhibitor therapy — once you’re back home.

No responsible facilitator can guarantee visa approval, treatment acceptance, treatment response, or survival.

How Shifam Health Supports International IDC Patients

Shifam Health is a medical tourism facilitator — not a hospital, oncology clinic, or diagnostic/pathology laboratory, and not a substitute for your treating physician. What we help coordinate:

• Sharing your imaging, biopsy, and pathology reports — including ER/PR/HER2 and genomic testing results, if available — with a partner hospital’s breast oncology team
• Requesting an itemized treatment and cost estimate, explicitly clarifying whether HER2-targeted therapy, immunotherapy, or CDK4/6 inhibitors are included
• Hospital and specialist shortlisting based on your specific diagnosis and biomarker profile
• Medical visa documentation support
• Airport pickup, accommodation guidance, and local coordination during treatment
• Interpreter support where needed
• Remote follow-up communication, including coordination of extended systemic therapy, once you’re back home

We don’t diagnose IDC, recommend a specific treatment, or guarantee outcomes — those decisions belong to you and your treating oncology team. Our role is to remove the logistical burden so you can focus on the medical decision itself.

If you or a family member has an IDC diagnosis and is exploring treatment options in India, share your reports with our team on WhatsApp or through a short inquiry form. There’s no obligation, and most patients hear back with an initial specialist review within 24–48 hours.

Frequently Asked Questions

People Ask Further